AstraZeneca: positive results from breast cancer trial

(CercleFinance.com) - AstraZeneca said on Wednesday that it has obtained positive clinical results from a Phase II trial with its antibody treatment for refractory HER2-positive metastatic breast cancer, a disease with high unmet need.


The Anglo-Swedish drugmaker and its Japanese partner Daiichi Sankyo today announced positive top-line results for trastuzumab deruxtecan (DS-8201) evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated.

The response rate - as assessed by an independent review committee - confirmed the "unprecedented clinical activity" of the Phase I trial, the companies said.

The safety and tolerability profile of trastuzumab deruxtecan was also consistent with previous data, they said.

These results are expected to support planned regulatory submissions in the second half of 2019, AstraZeneca and Daiichi Sankyo said.

Copyright (c) 2019 CercleFinance.com. All rights reserved.